Evidence map›Paper›PMID 37966940›Full record

ArticleJournal of the National Cancer Institute2024

Impact of pain and adverse health outcomes on long-term US testicular cancer survivors.

Paul C Dinh, Patrick O Monahan, Sophie D Fosså, Howard D Sesso, Darren R Feldman, M Eileen Dolan, Kathryn Nevel, John Kincaid, David J Vaughn, Neil E Martin and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 2 countries.

Paul C DinhDivision of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0003-0235-8519
Patrick O MonahanDepartment of Biostatistics and Health Data Science, Indiana University, Indianapolis, IN, USA.
Sophie D FossåDepartment of Oncology, Oslo University Hospital, Radiumhospital, Oslo, Norway.ORCID 0000-0002-3729-2217
Howard D SessoDivision of Preventive Medicine, Department of Medicine Research, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-9698-9954
Darren R FeldmanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2424-4635
M Eileen DolanDepartment of Medicine, University of Chicago, Chicago, IL, USA.ORCID 0000-0003-1613-097X
Kathryn NevelDivision of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0003-1499-837X
John KincaidDepartment of Neurology, Indiana University, Indianapolis, IN, USA.
David J VaughnDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Neil E MartinDepartment of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-8164-8516
Victoria A SanchezDepartment of Medical Engineering, University of South Florida, Tampa, FL, USA.ORCID 0000-0001-5033-6643
Lawrence H EinhornDivision of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0001-7971-7669
Robert FrisinaDepartment of Medical Engineering, University of South Florida, Tampa, FL, USA.ORCID 0000-0002-7423-6257
Chunkit FungDepartment of Medicine, J.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0002-9384-0732
Kurt KroenkeRegenstrief Institute, Inc, Indiana University, Indianapolis, IN, USA.ORCID 0000-0002-0114-4669
Lois B TravisDivision of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0002-6010-3541
Indiana University School of MedicineBrigham and Women's Hospital · USIndiana University – Purdue University Indianapolis · USUniversity of South Florida · USMemorial Sloan Kettering Cancer Center · USOslo University Hospital · NORegenstrief Institute · USUniversity of Chicago · USUniversity of Pennsylvania · USUniversity of Rochester Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI FRANCESCA M GANY · 1985 to 2026
$347.4M
Genetic Susceptibility and Biomarkers of Platinum-related ToxicitiesR01CA157823 · NCI · UNIVERSITY OF ROCHESTER · PI TRAVIS, LOIS B. · 2012 to 2025
$11.2M
Randomized Trial of Telehealth vs Conventional Hearing Care Delivery in the ACHIEVE StudyR01DC019408 · NIDCD · JOHNS HOPKINS UNIVERSITY · PI DEAL, JENNIFER ANNE, SANCHEZ, VICTORIA ANN · 2021 to 2025
$3.2M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA157823NCI NIH HHS R01 DC019408-01NIDCD NIH HHS R01 DC019408
6 · The paper itself

Abstract

backgroundNo study has quantified the impact of pain and other adverse health outcomes on global physical and mental health in long-term US testicular cancer survivors or evaluated patient-reported functional impairment due to pain.

methodsTesticular cancer survivors given cisplatin-based chemotherapy completed validated surveys, including Patient-Reported Outcomes Measurement Information System v1.2 global physical and mental health, Patient-Reported Outcomes Measurement Information System pain questionnaires, and others. Multivariable linear regression examined relationships between 25 adverse health outcomes with global physical and mental health and pain-interference scores. Adverse health outcomes with a β^  of more than 2 are clinically important and reported below.

resultsAmong 358 testicular cancer survivors (median age = 46 years, interquartile range [IQR] = 38-53 years; median time since chemotherapy = 10.7 years, IQR = 7.2-16.0 years), median adverse health outcomes number was 5 (IQR = 3-7). A total of 12% testicular cancer survivors had 10 or more adverse health outcomes, and 19% reported chemotherapy-induced neuropathic pain. Increasing adverse health outcome numbers were associated with decreases in physical and mental health (P < .0001 each). In multivariable analyses, chemotherapy-induced neuropathic pain (β^ = -3.72; P = .001), diabetes (β^ = -4.41; P = .037), obesity (β^ = -2.01; P = .036), and fatigue (β^ = -8.58; P < .0001) were associated with worse global mental health, while being married or living as married benefited global mental health (β^ = 3.63; P = .0006). Risk factors for pain-related functional impairment included lower extremity location (β^ = 2.15; P = .04) and concomitant peripheral artery disease (β^ = 4.68; P < .001). Global physical health score reductions were associated with diabetes (β^ = -3.81; P = .012), balance or equilibrium problems (β^ = -3.82; P = .003), cognitive dysfunction (β^ = -4.43; P < .0001), obesity (β^ = -3.09; P < .0001), peripheral neuropathy score (β^ = -2.12; P < .0001), and depression (β^ = -3.17; P < .0001).

conclusionsTesticular cancer survivors suffer adverse health outcomes that negatively impact long-term global mental health, global physical health, and pain-related functional status. Clinically important factors associated with worse physical and mental health identify testicular cancer survivors requiring closer monitoring, counseling, and interventions. Chemotherapy-induced neuropathic pain must be addressed, given its detrimental impact on patient-reported functional status and mental health 10 or more years after treatment.

Indexed as

Antineoplastic AgentsDiabetes MellitusNeoplasms, Germ Cell and EmbryonalNeuralgiaTesticular NeoplasmsAdultHumansMaleMiddle AgedObesityOutcome Assessment, Health CarePatient Reported Outcome MeasuresQuality of LifeSurvivorsAntineoplastic Agents

Identifiers

PMID37966940
PMCPMC10919346
OpenAlexW4388692478

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.